Clinical Trials
10 trialsNCT03792841 2025-10-16
Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC
Amgen
Phase 1 Terminated
NCT02092467 2021-08-17
Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis
Pfizer
Phase 4 Completed
NCT03780959 2019-08-02
Safety and Efficacy of Etanercept (Recombinant Human Tumor Necrosis Factor Receptor Fusion Protein [TNFR:Fc]) in Children With Juvenile Rheumatoid Arthritis (JRA)
Amgen
Phase 2/3 Completed
NCT01241591 2018-12-26
A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Pfizer
Phase 3 Completed
NCT01313221 2017-03-15
REFINE
Amgen
Phase 3 Completed
NCT00357903 2017-02-09
Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trials
Amgen
Phase 3 Completed
NCT00724672 2015-06-01
A Study of Immune Cells in Patients With Rheumatoid Arthritis During Different Types of Anti-TNF Alpha Treatments (Study P05521)
Merck Sharp & Dohme LLC
Withdrawn
NCT00111449 2013-05-15
Evaluating the Safety of Etanercept 50 mg Twice Weekly in Subjects With Psoriasis
Amgen
Phase 3 Completed
NCT00111436 2013-04-26
Evaluating the Safety of Etanercept in the Treatment of Psoriasis in Adult Subjects
Amgen
Phase 3 Completed
NCT00141791 2009-08-07
Study Evaluating Etanercept in Moderate to Severe Asthma
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 2 Completed